Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis
Authors:
- N Al‐MutairiNAN Al‐Mutairi
- Joshi ArunJAJoshi Arun
- Nour‐Eldin OsamaNONour‐Eldin Osama
- Zaki AmrZAZaki Amr
- Al‐Sheltawy MazenAMAl‐Sheltawy Mazen
- El‐Adawy IbtesamEIEl‐Adawy Ibtesam
- El‐Baghly NazehaENEl‐Baghly Nazeha
- 22 March 2004
- journal article
- review article
- Published by Wiley in International Journal of Dermatology
- Vol. 43 (11) , 847-851
Abstract
Background High‐dose intravenous immunoglobulin (IVIG) is emerging as a promising new therapy for treating the rare but potentially fatal drug reaction toxic epidermal necrolysis (TEN). Experimental in vitro studies support that IVIG can block the Fas‐FasL‐mediated apoptosis in TEN.Methods Twelve consecutive patients (7M, 5F) with TEN admitted over a 5‐year period from January 1998 to December 2002 were treated with a dose of 0.5–1.0 g/kg/d of IVIG for 4–5 days along with standard care protocol. Clinical outcome in terms of average duration to arrest the progression, complete healing, hospital stay, side‐effects and complications were determined to find the efficacy of IVIG treatment.Results Average age was 27.16 years (7–50 years). There were four children (2M, 2F) aged 7–12 years. One patient had an underlying malignancy. No patient had HIV infection. The average total body surface area involvement was 57.5% (30–90%). An IVIG infusion was started, on average, 1.58 days (1–3 days) after admission. All patients responded well to the treatment. There was no mortality. The disease progression was arrested in a mean of 2.83 days (1–5 days). Time taken for complete healing (re‐epithelialization) was 7.33 days (5–13 days). The average duration of hospital stay was 12.5 days (7–21 days). No side‐effects of the IVIG treatment were observed in these patients.The drugs triggering TEN in these patients were phenytoin (four patients), followed by penicillin (three), cotrimoxazole (two), phenobarbital and furosemide (one patient each), respectively. In one patient, the offending drug could not be ascertained.Conclusion Our experience of treating 12 patients with TEN using IVIG, in Kuwait, confirms that it is a safe and effective treatment for these patients.Keywords
This publication has 27 references indexed in Scilit:
- Toxic epidermal necrolysisThe Lancet, 1998
- Drug-induced hypersensitivity syndrome and toxic epidermal necrolysis. Treatment with N-acetylcysteineBritish Journal of Dermatology, 1997
- Use of intravenous immunoglobulin in the treatment of severe cutaneous drug reactions in patients with AIDSJournal of Allergy and Clinical Immunology, 1996
- Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysisBritish Journal of Dermatology, 1996
- Severe Adverse Cutaneous Reactions to DrugsNew England Journal of Medicine, 1994
- The Spectrum of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Clinical Classification.Journal of Investigative Dermatology, 1994
- Toxic Epidermal Necrolysis (Lyell Syndrome) in 77 Elderly PatientsAge and Ageing, 1993
- Efficacy of cyclophosphamide in toxic epidermal necrolysisJournal of the American Academy of Dermatology, 1991
- Improved Burn Center Survival of Patients with Toxic Epidermal Necrolysis Managed without CorticosteroidsAnnals of Surgery, 1986
- Phenytoin hypersensitivity reaction presenting with toxic epidermal necrolysis and severe hepatitisJournal of the American Academy of Dermatology, 1985